Connect Biopharma Holdings Limited Research and Development Expense
Connect Biopharma Holdings Limited (CNTB) reported Research and Development Expense of $16.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Connect Biopharma Holdings Limited research and development expense for the quarter ending 2026-06-30 was $16.27M, a 85.49% increase year-over-year.
- Connect Biopharma Holdings Limited research and development expense for the quarter ending 2026-03-31 was $15.03M, a 126.59% increase year-over-year.
- Connect Biopharma Holdings Limited research and development expense for the quarter ending 2025-12-31 was $11.28M, a 80.92% increase year-over-year.
- Connect Biopharma Holdings Limited research and development expense for the quarter ending 2025-09-30 was $11.11M, a 23.32% increase year-over-year.
- Connect Biopharma Holdings Limited research and development expense for fiscal 2025 was $37.80M, a 29.20% increase from fiscal 2024.
- Connect Biopharma Holdings Limited research and development expense for fiscal 2024 was $29.26M, a 44.80% decline from fiscal 2023.
- Connect Biopharma Holdings Limited research and development expense for fiscal 2023 was $53.00M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.27M 10-Q · filed 2026-08-12 | $31.30M 10-Q · filed 2026-08-12 | $42.59M derived: sum of 3 quarters · filed 2026-08-12 | $53.70M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $15.03M 10-Q · filed 2026-05-12 | $26.31M derived: sum of 2 quarters · filed 2026-05-12 | $37.42M derived: sum of 3 quarters · filed 2026-05-12 | $46.20M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $11.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $22.39M derived: sum of 2 quarters · filed 2026-03-31 | $31.16M derived: sum of 3 quarters · filed 2026-08-12 | $37.80M 10-K · filed 2026-03-31 |
| 2025-09-30 | $11.11M 10-Q · filed 2025-11-12 | $19.88M derived: sum of 2 quarters · filed 2026-08-12 | $26.52M 10-Q · filed 2025-11-12 | $32.75M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $8.77M 10-Q · filed 2026-08-12 | $15.41M 10-Q · filed 2026-08-12 | $21.64M derived: sum of 3 quarters · filed 2026-08-12 | $30.65M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $6.63M 10-Q · filed 2026-05-12 | $12.87M derived: sum of 2 quarters · filed 2026-05-12 | $21.88M derived: sum of 3 quarters · filed 2026-05-12 | $27.23M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $6.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $15.24M derived: sum of 2 quarters · filed 2026-03-31 | $20.59M derived: sum of 3 quarters · filed 2026-03-31 | $29.26M 10-K · filed 2026-03-31 |
| 2024-09-30 | $9.01M 10-Q · filed 2025-11-12 | $14.36M derived: sum of 2 quarters · filed 2025-11-12 | $23.02M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $5.35M 10-Q · filed 2025-08-13 | $14.01M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $8.66M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $53.00M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |